Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Change in Account Payables (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Change in Account Payables for 7 consecutive years, with -$2.9 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 168.03% to -$2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.4 million through Dec 2025, down 284.16% year-over-year, with the annual reading at $1.7 million for FY2025, 19.5% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$2.9 million at Outlook Therapeutics, down from $30255.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $4.2 million in Q4 2024, with the low at -$4.6 million in Q1 2025.